297 related articles for article (PubMed ID: 32473302)
1. Prognostic gene expression signature for high-grade serous ovarian cancer.
Millstein J; Budden T; Goode EL; Anglesio MS; Talhouk A; Intermaggio MP; Leong HS; Chen S; Elatre W; Gilks B; Nazeran T; Volchek M; Bentley RC; Wang C; Chiu DS; Kommoss S; Leung SCY; Senz J; Lum A; Chow V; Sudderuddin H; Mackenzie R; George J; ; Fereday S; Hendley J; Traficante N; Steed H; Koziak JM; Köbel M; McNeish IA; Goranova T; Ennis D; Macintyre G; Silva De Silva D; Ramón Y Cajal T; García-Donas J; Hernando Polo S; Rodriguez GC; Cushing-Haugen KL; Harris HR; Greene CS; Zelaya RA; Behrens S; Fortner RT; Sinn P; Herpel E; Lester J; Lubiński J; Oszurek O; Tołoczko A; Cybulski C; Menkiszak J; Pearce CL; Pike MC; Tseng C; Alsop J; Rhenius V; Song H; Jimenez-Linan M; Piskorz AM; Gentry-Maharaj A; Karpinskyj C; Widschwendter M; Singh N; Kennedy CJ; Sharma R; Harnett PR; Gao B; Johnatty SE; Sayer R; Boros J; Winham SJ; Keeney GL; Kaufmann SH; Larson MC; Luk H; Hernandez BY; Thompson PJ; Wilkens LR; Carney ME; Trabert B; Lissowska J; Brinton L; Sherman ME; Bodelon C; Hinsley S; Lewsley LA; Glasspool R; Banerjee SN; Stronach EA; Haluska P; Ray-Coquard I; Mahner S; Winterhoff B; Slamon D; Levine DA; Kelemen LE; Benitez J; Chang-Claude J; Gronwald J; Wu AH; Menon U; Goodman MT; Schildkraut JM; Wentzensen N; Brown R; Berchuck A; Chenevix-Trench G; deFazio A; Gayther SA; García MJ; Henderson MJ; Rossing MA; Beeghly-Fadiel A; Fasching PA; Orsulic S; Karlan BY; Konecny GE; Huntsman DG; Bowtell DD; Brenton JD; Doherty JA; Pharoah PDP; Ramus SJ
Ann Oncol; 2020 Sep; 31(9):1240-1250. PubMed ID: 32473302
[TBL] [Abstract][Full Text] [Related]
2. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.
Zhang Y; Liu J; Raj-Kumar PK; Sturtz LA; Praveen-Kumar A; Yang HH; Lee MP; Fantacone-Campbell JL; Hooke JA; Kovatich AJ; Shriver CD; Hu H
Breast Cancer Res Treat; 2020 Dec; 184(3):689-698. PubMed ID: 32880016
[TBL] [Abstract][Full Text] [Related]
5. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
[TBL] [Abstract][Full Text] [Related]
6. A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.
Jin C; Xue Y; Li Y; Bu H; Yu H; Zhang T; Zhang Z; Yan S; Lu N; Kong B
Int J Gynecol Cancer; 2018 Jan; 28(1):51-58. PubMed ID: 28976449
[TBL] [Abstract][Full Text] [Related]
7. Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.
Hillman RT; Chisholm GB; Lu KH; Futreal PA
J Natl Cancer Inst; 2018 Mar; 110(3):265-72. PubMed ID: 29584920
[TBL] [Abstract][Full Text] [Related]
8. Integrated weighted gene co-expression network analysis reveals biomarkers associated with prognosis of high-grade serous ovarian cancer.
Wang B; Chao S; Guo B
J Clin Lab Anal; 2022 Feb; 36(2):e24165. PubMed ID: 34997982
[TBL] [Abstract][Full Text] [Related]
9. Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
Benvenuto G; Todeschini P; Paracchini L; Calura E; Fruscio R; Romani C; Beltrame L; Martini P; Ravaggi A; Ceppi L; Sales G; Donati F; Perego P; Zanotti L; Ballabio S; Grassi T; Delle Marchette M; Tognon G; Sartori E; Adorni M; Odicino F; D'Incalci M; Bignotti E; Romualdi C; Marchini S
Int J Cancer; 2020 Jul; 147(2):565-574. PubMed ID: 32096871
[TBL] [Abstract][Full Text] [Related]
10. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
Li M; Cheng X; Rong R; Gao Y; Tang X; Chen Y
BMC Cancer; 2020 Oct; 20(1):1032. PubMed ID: 33109151
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Role of Zinc Finger Homeobox 4 in Ovarian Serous Cystadenocarcinoma.
Ha M; Kim J; Park SM; Hong CM; Han ME; Song P; Kang CD; Lee D; Kim YH; Hur J; Oh SO
Genet Test Mol Biomarkers; 2020 Mar; 24(3):145-149. PubMed ID: 32105524
[No Abstract] [Full Text] [Related]
12. The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer.
Schwede M; Waldron L; Mok SC; Wei W; Basunia A; Merritt MA; Mitsiades CS; Parmigiani G; Harrington DP; Quackenbush J; Birrer MJ; Culhane AC
Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):509-519. PubMed ID: 31871106
[TBL] [Abstract][Full Text] [Related]
13. Seven Genes Based Novel Signature Predicts Clinical Outcome and Platinum Sensitivity of High Grade IIIc Serous Ovarian Carcinoma.
Liu G; Chen L; Ren H; Liu F; Dong C; Wu A; Liu Z; Zheng Y; Cheng X; Liu L
Int J Biol Sci; 2018; 14(14):2012-2022. PubMed ID: 30585265
[No Abstract] [Full Text] [Related]
14. Development and validation of an individualized gene expression-based signature to predict overall survival of patients with high-grade serous ovarian carcinoma.
Yuan D; Zhu H; Wang T; Zhang Y; Zheng X; Qu Y
Eur J Med Res; 2023 Oct; 28(1):465. PubMed ID: 37884970
[TBL] [Abstract][Full Text] [Related]
15. A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer.
Cheon DJ; Tong Y; Sim MS; Dering J; Berel D; Cui X; Lester J; Beach JA; Tighiouart M; Walts AE; Karlan BY; Orsulic S
Clin Cancer Res; 2014 Feb; 20(3):711-23. PubMed ID: 24218511
[TBL] [Abstract][Full Text] [Related]
16. Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature.
Hinchcliff E; Paquette C; Roszik J; Kelting S; Stoler MH; Mok SC; Yeung TL; Zhang Q; Yates M; Peng W; Hwu P; Jazaeri A
Cancer Immunol Immunother; 2019 Sep; 68(9):1515-1526. PubMed ID: 31515669
[TBL] [Abstract][Full Text] [Related]
17. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
18. Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma.
Wang C; Block MS; Cunningham JM; Sherman ME; McCauley BM; Armasu SM; Vierkant RA; Traficante N; ; Talhouk A; Ramus SJ; Pejovic N; Köbel M; Jorgensen BD; Garsed DW; Fereday S; Doherty JA; Ariyaratne D; Anglesio MS; Widschwendter M; Pejovic T; Bosquet JG; Bowtell DD; Winham SJ; Goode EL
Cancer Epidemiol Biomarkers Prev; 2023 Apr; 32(4):542-549. PubMed ID: 36790339
[TBL] [Abstract][Full Text] [Related]
19. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
[TBL] [Abstract][Full Text] [Related]
20. T-cell activation is associated with high-grade serous ovarian cancer survival.
Wang L; Sun W; Zhang G; Huo J; Tian Y; Zhang Y; Yang X; Liu Y
J Obstet Gynaecol Res; 2022 Aug; 48(8):2189-2197. PubMed ID: 35334503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
